StoxCipla vs Max Healthcare Institute: share price & financials comparison
NSE: CIPLA vs MAXHEALTH · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Cipla vs Max Healthcare Institute at a glance
Cipla (CIPLA) has a market capitalisation of ₹1,12,437 Cr, against ₹92,182 Cr for Max Healthcare Institute (MAXHEALTH). Over the past year Cipla has returned -7.4%, compared with -16.8% for Max Healthcare Institute. On valuation, Cipla trades at a lower P/E of 38.8 versus 66.7. Max Healthcare Institute earns a higher return on equity (12.2% vs 8.2%). Cipla comes out ahead on size, valuation, financial health and technicals. Max Healthcare Institute comes out ahead on profitability, growth and momentum. Across the scored metrics below, Cipla leads on 8 and Max Healthcare Institute on 9. On StoxGud's 10-point checklist, Cipla scores 7/10 and Max Healthcare Institute scores 4/10.
| Metric | Cipla | Max Healthcare Institute |
|---|---|---|
| Size | ||
| Market cap | ₹1,12,437 Cr | ₹92,182 Cr |
| Revenue (latest FY) | ₹28,163 Cr | ₹8,373 Cr |
| Net profit (latest FY) | ₹3,879 Cr | ₹1,442 Cr |
| Valuation | ||
| P/E | 38.8 | 66.7 |
| P/B | 3.18 | 8.13 |
| Dividend yield | 1.15% | 0.16% |
| Profitability | ||
| Return on equity | 8.2% | 12.2% |
| Net profit margin | 10.3% | 15.1% |
| Operating margin | 17.0% | 26.8% |
| Growth | ||
| Revenue growth (YoY) | -2.4% | +20.3% |
| Net profit growth (YoY) | -35.1% | -15.5% |
| Revenue CAGR (multi-year) | +8.0% | +27.3% |
| Financial health | ||
| Debt to equity | 0.01 | 0.33 |
| Momentum | ||
| 1-month return | +4.7% | +10.0% |
| 1-year return | -7.4% | -16.8% |
| 3-year CAGR | +3.9% | +16.9% |
| 5-year CAGR | +8.2% | +21.1% |
| 10-year CAGR | +9.7% | — |
| Distance from 52W high | -9.4% | -19.8% |
| Technicals | ||
| RSI (14) | 68 | 89 |
| Price vs 200-day avg | +2.1% | -6.2% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Cipla | Max Healthcare Institute |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 7/10 | 4/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Cipla or Max Healthcare Institute?
Cipla has a market cap of ₹1,12,437 Cr and Max Healthcare Institute has a market cap of ₹92,182 Cr as of 13 Nov 2026.
Which has a lower P/E, Cipla or Max Healthcare Institute?
Cipla has the lower P/E: Cipla trades at 38.8 and Max Healthcare Institute at 66.7.
Which gave better returns in the last year, Cipla or Max Healthcare Institute?
Cipla did better: Cipla returned -7.4% and Max Healthcare Institute returned -16.8% over one year.
What is the difference between Cipla and Max Healthcare Institute?
Both are NSE-listed companies in Healthcare. Cipla is about 1.2 times the size of Max Healthcare Institute by market cap. In the latest financial year Cipla reported revenue of ₹28,163 Cr and Max Healthcare Institute ₹8,373 Cr. Operating margin is 17.0% for Cipla and 26.8% for Max Healthcare Institute. Debt to equity is 0.01 for Cipla and 0.33 for Max Healthcare Institute.
Which is better, Cipla or Max Healthcare Institute?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Cipla leads on 8 and Max Healthcare Institute on 9. Cipla is ahead on size, valuation, financial health and technicals. Max Healthcare Institute is ahead on profitability, growth and momentum. On StoxGud's rules-based checklist Cipla scores 7/10 and Max Healthcare Institute scores 4/10. This is information, not advice: consult a SEBI-registered adviser before investing.